In­ves­ti­ga­tors de­tail some of the hopes – and fears – be­hind Cel­lec­tis' off-the-shelf CAR-T

Cel­lec­tis is right at the cut­ting edge of de­vel­op­ing a new, off-the-shelf CAR-T that hopes to dis­rupt a mar­ket that has yet to be cre­at­ed. So far, about the on­ly tan­gi­ble hu­man ev­i­dence of its po­ten­tial dura­bil­i­ty has been seen in a pair of in­fants who were giv­en Cel­lec­tis’ $CLLS lead ther­a­py to ward off lethal cas­es of leukemia. And while an up­date on their con­di­tion shows that the two young pa­tients are still alive and do­ing well months af­ter treat­ment, one had to fight off graft-vs-host dis­ease trig­gered by the ther­a­peu­tic, a key sign of tox­i­c­i­ty that in­ves­ti­ga­tors are watch­ing close­ly.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.